Two randomized clinical trials demonstrated that discontinuation of ACE inhibitors or ARBs did not affect the clinical outcomes of patients hospitalized with COVID-19 [157,158], whereas in one randomized control trial that enrolled both outpatients and hospitalized patients with COVID-19, discontinuing ACE inhibitors or ARBs was shown to lead to a faster and better recovery without affecting the maximum disease severity [159]. Here, ACE is linked to COVID-19.